Dr. Flemming Ornskov, CEO of Shire, spoke recently about the "dramatic" changes to his company over the past year during the 35th Annual J.P. Morgan Healthcare Conference in San Francisco.
Ornskov described Shire as now the "undisputed leader in rare and highly specialized conditions." He said the company, founded 30 years ago in Great Britain, is now a global force.
"We've done that through, I think, smart acquisition, smart deployment of capital, very intense focus on innovation and research, whether it's internal or external," Ornskov said.
The webcast can be heard on Shire's website until mid-April.
Shire is working on products to help people in more than 100 countries with hematological, immunological, neurological, ophthalmic, gastrointestinal and oncological conditions.
